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a b s t r a c t
About a decade ago, the molecular determinants controlling the opening and closing of Cx43 gap
junction channels have been identified. Advanced biophysical approaches revealed a critical role for
structural rearrangements in the cytoplasmic loop and dimerization of the C-terminal tail, resulting in
binding of the C-terminal tail to the cytoplasmic loop and Cx43 gap junction channel closure during
cellular acidosis. This has spurred the development of Cx43-mimetic peptides and peptidomimetics that
interfere with these loop/tail interactions, thereby preventing the closure of Cx43 gap junctions, e.g. in
the heart upon ischemia. Recently, we found that loop/tail interactions control Cx43-hemichannel ac-
tivity but with an opposite effect. Binding of the C-terminal tail to the cytoplasmic loop is a requisite for
the opening of Cx43 hemichannels in response to different stimuli, like decreased extracellular [Ca2þ],
increased intracellular [Ca2þ], positive membrane potentials or ischemia. Strikingly, peptides that favor
the open state of Cx43 gap junctions like the L2 peptide inhibit Cx43-hemichannel opening. These tools
now provide unprecedented opportunities to selectively inhibit Cx43 hemichannels while maintaining
Cx43 gap junction communication, impossible to achieve with siRNA or knockdown approaches both
affecting gap junctions and hemichannels. These tools not only are very helpful to unravel the role of
Cx43 hemichannels in complex biological systems, but also hold therapeutic potential to counteract
excessive Cx43-hemichannel activity like in ischemia/reperfusion in the brain and the heart or to prevent
Cx43 hemichannel-mediated gliotransmitter release in the basal amygdala during memory consolidation
in response to emotional events.
This article is part of a Special Issue entitled ‘Connexin based channels’.
! 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Intercellular communication is critical for regulating a plethora
of physiological processes in many organs and tissues critical for
life, including the brain, heart, kidney, liver, pancreas, lung, ar-
teries, ovary, bone, inner ear, skin, lens, retina and cornea as most
important ones (Kar et al., 2012; Leybaert and Sanderson, 2012;
Saez et al., 2003). For instance, the synchronization of the
contraction of cardiomyocytes, the coordination of metabolic
networks in the brain and the generation of rhythmic contractions
in the arteries critically depend on the proteins that establish
intercellular communication, the connexins (Cx) and pannexins
(Panx)-protein family (Billaud et al., 2012; Delmar and Makita,
2012). These proteins are ubiquitously expressed in human tis-
sues and are encoded by 21 genes for Cxs and 3 genes for Panxs
(D’hondt et al., 2009; Scemes et al., 2009, 2007). These proteins
assemble in hexameric channel complexes (though Panx2 might
form an octamer (Ambrosi et al., 2010)), which can either function
as head-to-head-docked gap junction channels establishing direct
cell-to-cell contacts or free unapposed hemichannels establishing
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mits non-commercial use, distribution, and reproduction in any medium, provided
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release nodes for signaling molecules affecting neighboring cells
(D’hondt et al., 2009; Herve and Derangeon, 2012; Scemes et al.,
2009). It is well established that Cx isoforms can function both
as gap junction channels and hemichannels (Evans et al., 2006;
Kar et al., 2012). For Panx isoforms, recent evidence from over-
expression studies suggests that they may also function as gap
junction channels (Ishikawa et al., 2011) although still under
debate (Sosinsky et al., 2011). Moreover, Cx and Panx channels
may also appear at intracellular membranes, including the mito-
chondria and the endoplasmic reticulum (ER), where they may
function as nonjunctional channels. Cx43 found at the inner
mitochondrial membrane has been implicated in Kþ flux into the
mitochondria of cardiomyocytes (Miro-Casas et al., 2009), whereas
ER-localized Panx channels may function as intracellular Ca2þ-
leak/release channels (D’hondt et al., 2011; Ishikawa et al., 2011;
Vanden Abeele et al., 2006). Very recently, a new protein family,
Ca2þ-homeostasis modulator 1 (CALHM1), has been identified and
reported to resemble structurally and functionally Cx/Panx chan-
nels (Siebert et al., 2013). CALHM1 seems to function as a non-
junctional channel responsible for ATP release, especially in the
taste bud cells, involved in the sensation of bitter, sweet and
umami tastes (Taruno et al., 2013).
In this review, we will focus on the 43-kDa Cx isoform (Cx43),
which is highly and widely expressed, in particular in the heart and
the brain (Kar et al., 2012; Scemes et al., 2009). The biological role of
Cxs, including Cx43, as gap junction and nonjunctional channels
has recently and extensively been discussed in other reviews
(Chandrasekhar and Bera, 2012; Kar et al., 2012;Wang et al., 2013a).
In short, as reported in many cell types and tissues, Cx-based gap
junctions provide ionic/electrical conductance (Naþ, Kþ, Ca2þ),
metabolic coupling (ATP/ADP, glucose, glutamate, glutathione) and
spreading of secondary messenger molecules (IP3, cAMP) between
cells (Kar et al., 2012). Also, Cx-based hemichannels mediate the
flux of many substances, including ions and molecules with a mo-
lecular weight (MW) lower than 1e2 kDa, including ATP, NADþ,
glutamate, glutathione, prostaglandin E2 and epoxyeicosatrienoic
acids (D’hondt et al., 2009; Wang et al., 2013a). These molecules
provide local/paracrine signaling networks implicated in the con-
trol and coordination of intracellular and intercellular signaling
pathways involved in cell survival, proliferation and death (Decrock
et al., 2013, 2009b; Leybaert and Sanderson, 2012). The physio-
logical role of Cx hemichannels has been questioned (Scemes,
2012), although it is increasingly clear that diverse stimuli within
physiological conditions can modulate the opening of Cx hemi-
channels, including low extracellular [Ca2þ] as occurs during
neuronal synaptic signaling (Torres et al., 2012), moderate elevation
of intracellular [Ca2þ] in the physiological range of w500 nM (De
Vuyst et al., 2006; De Vuyst et al., 2009; Wang et al., 2012, 2013a)
and mechanical forces/shear stress (Loiselle et al., 2012). Further-
more, physiological elevations of intracellular [Ca2þ] shifted the
threshold for voltage-dependent opening of Cx43 hemichannels
from þ60 mV to þ40 mV and lower (Wang et al., 2012). This in-
dicates that physiological Ca2þ signaling may sensitize the opening
of Cx43 hemichannels in response to membrane polarization to
potentials in the þ30e40 mV range which may occur in electrically
excitable cells. On the other hand, the excessive opening of Cx
hemichannels can be limited physiologically by the actomyosin
cytoskeleton involving Ca2þ and RhoA signaling, thus avoiding
detrimental effects on cellular homeostasis (Ponsaerts et al., 2008,
2012a,b). Finally, post-translation modifications can also influence
and regulate the activity of Cx43 hemichannels (Johnstone et al.,
2012).
The monomeric Cx43-building blocks that form hexameric
channels consist of a 382 amino acid-long protein (based on the
human Cx43 sequence; NCBI Reference Sequence: NP_000156.1)
containing four-transmembrane domains with two extracellular
loops, one cytoplasmic loop domain and an N- and C-terminus
that faces the cytoplasmic side. The N-terminus is relatively short
(13 amino acids), while the C-terminus is relatively long (w150
amino acids). The C-terminus is very important for the regulation
of Cx43-gap junction channels, containing a number of phos-
phorylation sites, protein-interaction sites and motifs as well as
redox-sensitive residues (three Cys residues) (Herve et al., 2007;
Johnstone et al., 2012; Palatinus et al., 2012; Solan and Lampe,
2009). In this review, we will focus on the role of loop/tail in-
teractions for controlling the activity of Cx43 gap junction chan-
nels and hemichannels. We will also discuss how recent insights
on the key determinants underlying loop/tail interactions and
their functional outcome for Cx43 gap junction channels and
hemichannels has spurred the development of novel peptides and
peptidomimetics with therapeutic potential. In particular, recent
advances resulted in the identification of peptides that can sus-
tain gap junction coupling in disease conditions and peptides that
can prevent excessive hemichannel opening under certain path-
ological conditions (Evans et al., 2012). These peptides are
promising tools to explore the role of gap junctions and Cx
hemichannels in pathological conditions and diseases, and offer
interesting possibilities towards defining novel molecular thera-
peutic targets (De Vuyst et al., 2011; Evans et al., 2012; Herve and
Dhein, 2010).
2. Intramolecular loop/tail interactions in Cx43 gap junction
channels and their functional consequences
2.1. Gap junction channels paved the path
About twenty years ago, the role of intramolecular interactions
in the gating of Cx43 gap junction channels started to emerge (Liu
et al., 1993). The original findings were directed towards providing
a mechanistic basis for the intracellular acidification-mediated
closure of Cx43 gap junction channels (Spray et al., 1981), but
were also found to be applicable to other forms of chemical gating,
for example gap junction closure induced by insulin (Homma et al.,
1998). Liu et al. found that Cx43-based gap junction channels were
particularly sensitive to a decrease in intracellular pH (pHi)
compared to Cx32 or CT-truncated Cx43 (Cx43M257)-based gap
junction channels (Liu et al., 1993). The junction conductance
rapidly decreased starting from pHi 6.8 and lower for Cx43, while
for Cx32 and Cx43M257, junction conductance only started to
decrease from pH 6.3 and below (Fig. 2 Q1). Hence, the C-terminal tail
of Cx43 seemed critical for the pH-dependent gating of the Cx43
gap junction channels. Further work revealed critical elements in
the cytoplasmic loop and its preceding transmembrane domain
(transmembrane domain 2, see Fig. 3), revealing a critical role for
His95 (Ek et al., 1994). Replacing His95 to Asp or Tyr led to func-
tional Cx43 gap junctions that displayed a decreased susceptibility
towards intracellular acidification. In contrast, replacing His95 to
Lys led to functional Cx43 gap junctions that displayed an increased
susceptibility towards intracellular acidification. Thus, His95 is
critical for the pH-dependent regulation of Cx43 gating, likely via a
protonation mechanism that would lead to a positively charged
residue, strengthening the interaction with the negatively charged
CT. Follow-up studies showed that the lack of sensitivity of
Cx43M257 gap junction channels to intracellular acidification (in the
range between pH 7.2 to pH 6.4) was restored upon co-expression
of the C-terminal tail (amino acids 259e382) (Morley et al., 1996).
Hence, the C-terminal tail of Cx43 acts as a separate and inde-
pendent domain that binds to a regionpreceding the C-terminal tail
and closes Cx43-gap junction channels upon intracellular acidifi-
cation. Elements in the first 257 amino acids were proposed to act
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as a receptor for elements in the last 124 amino acids, acting as a
particle (Morley et al., 1996). Two regions within the C-terminal tail
of Cx43 were found to be particularly critical for intracellular
acidification-induced uncoupling, one region covers amino acids
261e300 and another region covers amino acids 374e382 (Ek-
Vitorin et al., 1996). Deleting these two regions in Cx43 renders
these gap junction channels relatively insensitive to intracellular
acidification-induced uncoupling. Region 261e300 contains a
proline-rich region, identified as the SH3-binding domain of Src, a
protein tyrosine kinase (Kanemitsu et al., 1997; Sorgen et al.,
2004a). Pro277 and Pro280 seem to play a critical role in the
structural integrity of this region. Mutating these Pro residues into
Ala results in Cx43 gap junction channels resistant to intracellular
acidification, which mimics the behavior of Cx43D261"300 gap
junction channels. Region 374e382, which corresponds to the
PDZ2-binding site for Zonula Occludens-1 (ZO-1) (Giepmans and
Moolenaar, 1998; Sorgen et al., 2004a), also contains two Pro resi-
dues (Pro375 and Pro377) and a set of positively (Arg374 and
Arg376) and negatively charged residues (Asp378, Asp379 and
Glu381). The three negative charges seemed critical for the pHi
gating of the Cx43 gap junction channels, as the simultaneous
mutation of these residues abolished the pHi-induced closure of
these channels. Thus, interactions of the particle with its receptor
domain seem to depend on ionic and non-ionic interactions. These
concepts may not necessarily be limited to domain interactions
within Cx43, but may also be applicable for some other Cx isoforms,
like Cx40 (Gu et al., 2000; Stergiopoulos et al., 1999). Certainly, not
all Cx isoforms display this regulation. For example, C-terminal
truncation of Cx45 did not affect its pHi-dependent regulation
(Stergiopoulos et al., 1999). Furthermore, also hetero-domain in-
teractions may occur, as shown between Cx43 and Cx40. The pHi-
dependent regulation of C-terminally truncated Cx43 could be
restored by the C-terminal tail of Cx40 and vice versa, while the C-
terminal tail of Cx43 could render Cx26 and Cx32, which normally
are resistant to chemically-induced closure, sensitive to insulin
(Stergiopoulos et al., 1999). All these functional studies hinted to-
wards a critical role for the C-terminal tail of Cx43 in pHi-depen-
dent regulation of Cx43 gap junction channels through
intramolecular interactions. A detailed molecular analysis using
different biophysical approaches led to the identification of the
second part of the cytoplasmic loop (the L2 region corresponding to
amino acids 119e144 of Cx43) as the receptor for the C-terminal tail
particle (Duffy et al., 2002) (Fig. 3). The authors showed a pH-
dependent interaction between the L2 region and the C-terminal
tail of Cx43. A strong interaction between L2 and the C-terminal tail
of Cx43 was observed at pH 6.5, while binding was not observed at
pH 7.4. Importantly, the L2 region contains two His residues
(His126 and His144), which are protonated at low pH and are likely
involved in structural rearrangements of the L2 region (Fig. 2).
These two His residues are located in two separate regions that
were shown to form alpha helices in the solution structure of the L2
region obtained at pH 5.8. The critical role of these His residues in
the gating of Cx43 gap junction channels was further underpinned
by the analysis of Cx43H144E gap junction channels (Shibayama
et al., 2006). These channels displayed a reduced occurrence in
the residual state and a prolonged dwelling in the open state; very
similar to C-terminally truncated Cx43 channels. These functional
observations are underpinned by evidence from NMR studies
showing that an L2 peptide in which His144 was changed into Glu
displayed i) a decrease in the interaction with the C-terminal tail of
Cx43 and ii) a disrupted secondary structure (Shibayama et al.,
2006). In contrast to L2, the solution structure of L2H144E failed to
form two alpha-helical regions at pH 5.8. Besides the role of the L2
region in channel closure upon acidosis, this region also seems
important for proper channel-pore organization. Indeed, gap
Fig. 2. Function of C-terminally truncated Cx43 gap junctions and hemichannels. Gap
junctions: C-terminally truncated Cx43 gap junctions remain open, but are resistant to
low pHi-induced closure. Hemichannels: C-terminally truncated Cx43 hemichannels
remain closed, even at low pHi or other stimuli, like decreased extracellular [Ca2þ] or
increased intracellular [Ca2þ]. As in Fig. 1, only monomeric building blocks are shown
for clarity.
Fig. 1. Schematic representation of Cx43 gap junctions and hemichannels in the open
and closed state. The Cx43 protein is the building block for gap junctions and hemi-
channels, consisting of a short N-terminus, 4 transmembrane domains, two extracel-
lular loops, one cytoplasmic loop and a long C-terminal tail. Functional channels
consist of hexameric structures that are head-to-head docked to form gap junctions or
that are unopposed to form hemichannels. Gap junctions: At normal conditions
(pH > 7.0), gap junctions are open (green) and the C-terminal tail does not interact
with the cytoplasmic loop. During ischemia (or other conditions that cause a drop in
pH), the C-terminal tail dimerizes and the cytoplasmic loop restructures adopting two
alpha-helical structures at the proximal and distal part of the L2 region, resulting in the
binding of the C-terminal tail to the cytoplasmic loop and the closure of gap junction
channels (red). Peptides like L2 (but also others) interfere with these loop/tail in-
teractions by replacing the endogenous cytoplasmic loop of Cx43 and serving as a
binding partner for the C-terminal rail, maintaining the open state of gap junction
channels (green). Hemichannels: At normal condtions (pH w7.0), hemichannels are
closed (red) due to the lack of the binding of C-terminal tail to the cytoplasmic loop.
During ischemia, but also other conditions that open hemichannels like a decrease in
extracellular [Ca2þ] or increase in intracellular [Ca2þ] (up to 500 nM), hemichannels
are opened (green) due to the binding of the C-terminal tail to the cytoplasmic. Pep-
tides like L2 and Gap19 interfere with the loop/tail interactions by binding to the C-
terminal tail and preventing endogenous loop/tail interactions that are critical for
hemichannel opening. For clarity reasons, the monomeric building blocks are depicted,
but it should be noted that the functional hemichannel unit is hexameric.
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junctions formed by Cx43 carrying L2-subregion deletions caused a
loss of electrical communications, despite their ability to form
plaques (Seki et al., 2004a). Furthermore, the interaction between
the loop and the C-terminal tail at low pH may also depend on
homo-oligomerization, which is induced upon intracellular acidi-
fication (Hirst-Jensen et al., 2007). Different regions in the C-ter-
minal tail are involved in the homodimerization of the C-terminal
tail, including regions covered by amino acids 281e295, 299e304,
314e327, 340e348 and 364e382. These regions display consider-
able overlap with regions involved in the interaction with the
cytoplasmic loop. Regions covered by amino acids 343e346 and
377e379 strongly contributed to cytoplasmic loop binding, while
regions covered by amino acids 312e332, 335e340, 347e349, 357e
361, 364e374 and 380e382 weakly contribute to cytoplasmic loop
binding. Importantly, deletion of regions that affect homo-
dimerizations also affects the binding of the cytoplasmic loop
domain. Based on these findings, it was proposed that dimerization
of the C-terminal tail upon low pH is critical for interactionwith the
cytoplasmic loop domain (Hirst-Jensen et al., 2007). Beyond its role
in chemical gating of Cx43, the C-terminal tail regulates the local-
ization, number and size of Cx43 plaques in vivo, probably through
interaction with accessory proteins (Maass et al., 2007). These
accessory proteins and post-translational modifications may also
control the closure of Cx43 gap junction channels. For instance,
binding of Src via its SH3 domain and SH2 domain to the proline-
rich region and the phosphorylated Tyr265 residue of Cx43,
respectively, leads to Src-mediated phosphorylation of Cx43 on
Tyr247 (Kanemitsu et al., 1997). Mutations in the SH3-binding
domain of Cx43 of Tyr265 result in defective Src binding and
phosphorylation. Expression of Src and phosphorylation of Tyr247/
265 disrupts Cx43-mediated gap junction communication between
cells, but not in cells expressing Cx43Y265F or Cx43D265 (Giepmans
et al., 2001). Physiological Src signaling occurs downstream of G-
protein-coupled receptor signaling, leading to the loss of cellecell
communication (Postma et al., 1998). Interestingly, the binding of
Src to Cx43 is highly pH-dependent, being enhanced at low pH
(Duffy et al., 2004). Another important binding partner of the C-
terminal tail of Cx43 is the scaffolding protein ZO-1 (Giepmans and
Moolenaar, 1998; Toyofuku et al., 1998), which stabilizes Cx43 gap
junction channel formation (Giepmans and Moolenaar, 1998), de-
termines the size of gap junctions (Hunter et al., 2005) and locali-
zation of gap junctions (Palatinus et al., 2011a), and regulates the
rate of connexon docking (Rhett et al., 2011). Increased binding of
constitutively active Src to Cx43 coincided with decreased Cx43/
ZO-1-complex formation (Toyofuku et al., 2001). This interdepen-
dence is underpinned by the fact that the increased binding of Src
to Cx43 at low pH also prevents and reversed the binding of ZO-1 to
Cx43, resulting in ZO-1-stripped Cx43-gap junction channels
(Duffy et al., 2004). As a consequence of this, the internalization of
Cx43 gap junctions is enhanced. To summarize, intracellular acid-
ification, as occurs during ischemia, leads to the closure of Cx43-
based gap junction channels through an increased dimerization
of the C-terminal tail and concomitant structural arrangement in
the cytoplasmic domain of Cx43, resulting in a binding of the C-
terminal tail to the cytoplasmic domain. In addition, low intracel-
lular pH will result in the stripping of ZO-1 from Cx43 gap junction
channels through the recruitment of Src, which facilitates the
closure of Cx43 gap junction channels and ultimately results in an
increased internalization of Cx43 gap junction channels and a
reduced fraction of plasmalemmal Cx43 gap junctions. In any case,
the C-terminal tail, its binding partners and post-translational
modifications are dispensable for the targeting and the formation
of functional Cx43 gap junction channels (Hunter and Gourdie,
2008; Maass et al., 2007).
Fig. 3. Amino acid presentation of a Cx43-building block and its relevant regions for loop/tail and tail/tail interactions. The Cx43 building block contains different hot spots for loop/
tail and tail/tail interactions. Residues in the C-terminal tail involved in binding the cytoplasmic loop are indicated with a red *, while the residues involved in C-terminal tail
dimerization are indicated with a blue ¼. Four relevant Cx-mimetic peptide sequences are indicated: L2 (orange line), Gap19 (red line), SH3 (light blue line) and CT9 (dark blue line).
In most cases, these peptides are fused to cell-penetrating sequences like TAT or antennapedia to facilitate cell-entry, except for Gap19, which displays endogenous cell-penetrating
properties. The L2 region contains two His residues (His126 and His144; black circles) that are critical for forming alpha helices upon a decrease in pH and for binding the C-terminal
tail. Residues Ile130 (blue circle) and Lys134 (green circle) seem important for interaction with the CT9 region, which contains different important residues, like Asp378 and Asp379
(green circles). These negatively charged residues are believed to be important for ionic interactions with positively charged residues in the L2 region, while other hydrophobic
residues may be involved in non-ionic interactions with the L2 region. Furthermore Pro375 and Pro377 may contribute to the proper structural organization of these residues. This
figure has been adapted from Lampe and Lau (2000). Reprinted from Archives of Biochemistry and Biophysics, 384(2), Paul D. Lampe and Alan F. Lau, Regulation of Gap Junctions by
Phosphorylation of Cxs, 205e215, Copyright ! 2000 Academic Press, with permission from Elsevier.
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2.2. Loop and C-terminal tail Cx43-mimetic peptides and their
effects on Cx43 gap junction channels
In this section, we provide a systematic overview of the different
peptides and peptide-derived molecules that are based on intra-
cellular Cx43 sequences proposed to be involved in loop/tail in-
teractions. These peptides and peptide-derivedmolecules therefore
are believed to target the critical regions in the cytoplasmic loop or
C-terminal tail, thereby preventing the occurrence of “endogenous”
Cx43 loop/tail interactions that result in the closure of Cx43 gap
junction channels.
2.2.1. The SH3-binding domain peptide
A 17-mer peptide corresponding to amino acids 271e287
(CSSPTAPLSPMSPPGYK), which is the proline-rich region forming
the SH3-binding domain for Src, was used as amolecule to interfere
with the pHi-dependent gating of Cx43 gap junction channels
(Calero et al., 1998) (Fig. 3). Injection of this peptide in Cx43-
expressing and pair-forming oocytes completely abolished the
intracellular acidification-mediated closure of Cx43 gap junction
channels, while normal pHi-dependent gating was observed in cells
injected with a scrambled version (Calero et al., 1998). The mech-
anism could involve different possibilities. The 17-mer peptide
could act as the direct target for the receptor located in the cyto-
plasmic loop, thereby preventing the binding of the C-terminal tail
to the loop. In addition, this 17-mer peptide also partially overlaps
with regions responsible for C-terminal tail dimerization, an
important step in the binding of the cytoplasmic loop and inhibi-
tion of Cx43 gap junction channels (Hirst-Jensen et al., 2007).
Finally, this 17-mer peptide can also interfere with the recruitment
of Src to Cx43 and the subsequent Tyr265 phosphorylation of Cx43
(known to inhibit Cx43 gap junction channels), thereby preventing
Src-mediated Cx43 gap junction inhibition at low pH (Kanemitsu
et al., 1997).
2.2.2. The C-terminal CT9 peptide
A 9-mer peptide corresponding to the last 9 amino acids of the
C-terminal tail of Cx43 (CT9) has been developed (Fig. 3). This
sequence has different biological properties, including binding to
the cytoplasmic loop domain (Hirst-Jensen et al., 2007; Ponsaerts
et al., 2010), binding to the PDZ-2 domain of ZO-1 (Hunter et al.,
2005; Sorgen et al., 2004a) and increasing PKC-epsilon-mediated
phosphorylation of Cx43 after left ventricular injury in a cryo-
injury model (O’Quinn et al., 2011; Palatinus et al., 2011b). A cell-
permeable version of the CT9 peptide, called ACT1, was devel-
oped by Gourdie and co-workers, serving as an inhibitor of ZO-1
interaction by targeting its PDZ2 domain (Hunter et al., 2005).
ACT1 caused an increase in Cx43 gap junction size by facilitating
the transfer fromnonjunction Cx43 pools into gap junction plaques,
a process that seems to be limited and tightly controlled by ZO-1
(Hunter et al., 2005). ACT1 decreased the interaction of Cx43 with
ZO-1 at the perinexus, thereby increasing the presence of Cx43 as
gap junctions and decreasing its presence as hemichannels
(Palatinus et al., 2012; Rhett and Gourdie, 2012). As a consequence
of this shift in gap junction/hemichannel ratio, ACT1 increased
Cx43 gap junction communication and decreased Cx43-
hemichannel function. These effects were related to altered ZO-1
function, since ZO-1 knockdown recapitulated these effects of
ACT1. Also, ACT1 seems to provide a relatively rapid shift in Cx43
gap junction partitioning, which occurred within 2 h of ACT1
exposure to cells (Rhett et al., 2011). In any case, while these ACT1
effects on gap junctions seem to represent a remodeling of the
amount of Cx43 gap junctions, it is clear that ACT1 does not inhibit
Cx43 gap junction channel activity. The accumulation of Cx43 gap
junctions upon ACT1 treatment seems to be beneficial for wound
healing in a variety of conditions (Ghatnekar et al., 2009; Gourdie
et al., 2006; Rhett et al., 2008).
Very recently, ACT1 has been applied in a cryo-injury model of
the left ventricle, which was proposed to be relevant for ventricular
arrhythmias (O’Quinn et al., 2011). The latter has been associated
with Cx43 gap junction remodeling, which also occurred in the
wound and injury border zone. ACT1 exposure prevented Cx43 gap
junction remodeling, thereby suppressing arrhythmic behavior of
the heart and increasing ventricular depolarization rates up to 7e9
days after the injury. While control samples displayed an increased
lateralization of Cx43 associated with Cx43 dephosphorylation,
ACT1-treated samples displayed an improved accumulation of
Cx43 at the intercalated disks. ACT1 partially prevented Cx43
dephosphorylation by increasing the PKC-epsilon-mediated phos-
phorylation of Ser368 of Cx43 at thewound and injury border zone.
Interestingly, ACT1 also stimulated PKC-epsilon-mediated phos-
phorylation of recombinantly expressed and purified C-terminal
tail of Cx43 in vitro, while PDZ-2 of ZO-1 counteracted this process.
These cardioprotective effects of ACT1 on Cx43 phosphorylation fits
the earlier reports showing that PKC-epsilon prevented Cx43 gap
junction remodeling during transient ischemia (Ek-Vitorin et al.,
2006) or during global ischemia after ischemic pre-conditioning
(Srisakuldee et al., 2009).
2.2.3. The L2 peptide
As discussed above, the L2 region in the cytoplasmic loop
domain was shown to function as a receptor for the C-terminal tail
(Duffy et al., 2002). Binding of the C-terminal tail to the L2 region is
known to close Cx43 gap junction channels, like during low pHi/
ischemic conditions (Duffy et al., 2002; Ek-Vitorin et al., 1996;
Morley et al., 1996). Based on these findings, a peptide corre-
sponding to the L2 region of Cx43 (amino acids 119e144) has been
developed (Seki et al., 2004b) (Fig. 3). Application of this peptide
did not alter the unitary conductance of Cx43 gap junction chan-
nels, but decreased the frequency of transitions into the residual
state, increased the open time and altered the voltage dependence
of the Cx43 gap junction channels. These effects resembled the
results obtained with Cx43M257. Furthermore, the L2 peptide was
also shown to bind the C-terminal tail of Cx43 at pH 6.5. A mutant
L2 peptide (L2H126K/I130N) was not able to bind Cx43’s C-terminal
tail and did not affect Cx43 gap junction channel properties. These
mutations, which occur in the region that corresponds to the first
alpha-helix, likely disrupt the structural elements in this peptide
needed for interaction with the C-terminal tail. In follow-up
studies, another L2 mutant peptide was analyzed. L2H142E, which
lacked the second His critical for the formation of the second alpha-
helix in the L2 peptide, failed to bind the C-terminal tail of Cx43 and
modulate Cx43 gap junction channel properties in electrophysio-
logical experiments (Shibayama et al., 2006). Thus, L2 peptides by
preventing intramolecular loop/tail interactions seem to favor the
open state of Cx43 gap junction channels in response to high
transjunctional voltage ($þ60 mV).
2.3. Non-Cx43-mimetic peptides modulating Cx43 gap junctions
2.3.1. RXP-E peptide
An unbiased peptide screen for binding the C-terminal tail of
Cx43 resulted in the identification of novel peptides that could
modulate Cx43 gap junctions by targeting intramolecular in-
teractions (Shibayama et al., 2006). In particular, peptides con-
taining the RXP motif were found to preferably target the C-
terminal tail of Cx43 (Shibayama et al., 2006). Further optimization
studies resulted in an RXP-E peptide that binds the C-terminal tail
of Cx43 with high affinity. Importantly, in electrophysiological ex-
periments in N2a cells ectopically expressing Cx43, RXP-E
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increased the mean open time of Cx43 gap junction channels and
partially prevented the closure of Cx43 gap junction channels in
response to octanol or acidosis. Importantly, the effect of RXP-E on
octanol-induced uncoupling of Cx43 gap junctions required the
presence of the C-terminal tail of Cx43. Indeed, RXP-E was not able
to alleviate the octanol-triggered uncoupling of Cx43M257-based
gap junctions, although there was a delay in octanol inhibition,
suggesting an additional target outside the C-terminal tail of Cx43.
NMR studies led to the identification of two RXP-E-binding regions
in the C-terminal tail of Cx43, covering amino acids 343 to 346
(region 1) and 376e379 (region 2) (Shibayama et al., 2006).
Importantly, region 1 has been found to be important for pH-
dependent dimerization of the C-terminal tail of Cx43 (Sorgen
et al., 2004b), while region 2 was identified as the PDZ-2-binding
site of ZO-1 (Sorgen et al., 2004a). Thus, RXP-E peptide might be
very potent, since it displays two separate molecular and biological
properties, thereby interfering with intramolecular interactions
underlying C-terminal tail dimerization and with intermolecular
interactions underlying the recruitment of ZO-1. The effects of RXP-
E were further assessed in monolayer cultures of cardiomyocytes
isolated from neonatal and adult rats (Lewandowski et al., 2008),
revealing that RXP-E i) was able to bind the cardiac Cx43, ii) alle-
viated Cx43 gap junction uncoupling upon heptanol and intracel-
lular acidosis, and iii) prevented the block of action potential
propagation upon intracellular acidosis. Further work resulted in
the development of two novel pharmacophores, a cyclized hepta-
peptide (called CyRP-71) and a linear octapeptide of sequence
RRNYRRNY, promoting Cx43 gap junction channel opening (Verma
et al., 2009). The identification of the core structural elements in
the RXP-E peptide (RRXY) has spurred the development of the
first peptidomimetic molecule, AcRRK(4-HO-Benzoyl)-NH2, called
ZP2519, that prevented the closure of Cx43 gap junctions upon
heptanol exposure or intracellular acidosis by targeting the C-ter-
minal tail of Cx43 (Verma et al., 2010).
2.3.2. AAP10 and ZP123
About twenty years ago, a synthetic peptide called AAP10
(GAG-4Hyp-PY-CONH2) was found to display anti-arrhythmic ef-
fects (Dhein et al., 1994) and this could be linked to effects on Cx43
expression and function via a PKC-dependent mechanism (De
Vuyst et al., 2011; Easton et al., 2009; Hagen et al., 2009; Herve
and Dhein, 2006). AAP10 is based on the natural anti-arrhythmic
peptide AAPnat (HeGlyeProeHypeGlyeAlaeGly) that was iso-
lated from bovine atria and further synthetically improved (Dhein
et al., 1994; Grover and Dhein, 2001). Application of AAP10 (even
at very low concentration of 10 and 50 nM) enhanced gap junction
conductance in adult guinea pig cardiomyocytes, which are pre-
dominantly coupled via Cx43 and in HeLa cells ectopically
expressing Cx43 (Weng et al., 2002). The stimulatory effect of
AAP10 on gap junction conductance was dependent on PKCalpha
activity. AAP10 enhanced the activity of PKCalpha, thereby pro-
moting PKCalpha-dependent phosphorylation of Cx43. These
peptides were further used to counteract Cx43 gap junction
remodeling in heart failure models. For instance, acute hypoxia in
rat hearts leads to a decrease in Cx43 expression, reduced Cx43
phosphorylation and redistribution of Cx43 from gap junctions
into intracellular pools, resulting in decreased gap junction
communication (Wang et al., 2007). AAP10 prevented Cx43
dephosphorylation during acute hypoxia and increased total Cx43
levels (mainly in the phosphorylated form), thereby preventing
shut down of gap junction communication in the heart. In acute
regional myocardial ischemia, AAP10 prevented the decrease in
Cx43 phosphorylation in the ischemic region, but had no effect on
Cx43 phosphorylation in the non-ischemic region (Jozwiak and
Dhein, 2008). The decrease in Cx43 phosphorylation was
associated with Cx43 redistribution in the ischemic zone, which
could be prevented by AAP10 treatment. However, peptides based
on L-amino acids display a poor stability in in vivo systems.
Therefore, a new anti-arrhythmic peptide was developed, ZP123
(rotigapeptide), representing a retro-all-D-amino acid design of the
AAP10 template (AceDeTyreDeProeDe4HypeGlyeDeAlaeGlye
NH2) (Dhein et al., 2003; Wit and Duffy, 2008). ZP123 too
enhanced Cx43 gap junction conductance in a PKCalpha-
dependent manner, but with enhanced enzymatic stability in
in vivo applications. Consistent with its positive effect on gap
junction conductance, rotigapeptide also prevented the closure of
gap junction channels by acidosis (Eloff et al., 2003), thereby
maintaining intercellular coupling, diminishing the slowing down
of conduction velocity and the heterogeneity in repolarization. All
these influences contribute to anti-arrhythmic effects. Rotigapep-
tide also preserved the conduction of the atria during metabolic
stress (Haugan et al., 2005) and upon atrial fibrillation (Guerra
et al., 2006; Shiroshita-Takeshita et al., 2007). In open-chest
dogs undergoing ischemia/reperfusion and rats with chronic
myocardial infarction, spontaneous arrhythmias and infarct size
were reduced by rotigapeptide treatment (Haugan et al., 2006;
Hennan et al., 2006). Again, these effects likely are due to main-
tained Cx43 phosphorylation (e.g. at Ser297 and Ser368), which is
indeed to form functional gap junction channels (Axelsen et al.,
2006). Interestingly, rotigapeptide has been applied to explanted
heart from end-stage heart failure patients and resulted in an
improved conduction velocity (Wiegerinck et al., 2009). However,
in healing infarct border zone partial reversal of Cx43 remodeling
seemed not be sufficient to restore normal conduction or prevent
arrhythmias (Macia et al., 2011).
3. Intramolecular loop/tail interactions are essential for
Cx43-hemichannel opening
3.1. Cx43 hemichannels and gap junction channels display opposite
outcomes to signaling molecules
There is increasing evidence from several labs that gap junc-
tions and hemichannels may be influenced in an opposite manner
by signaling molecules or intracellular events. For instance, it is
well established that metabolic inhibition associated with
ischemia/reperfusion lead to closure of Cx43 gap junction chan-
nels in the heart (Duffy et al., 2004; Johansen et al., 2011; Severs,
1994), while promoting the opening of Cx43 hemichannels,
resulting in ionic leakage, intracellular Ca2þ and Naþ overload and
cell death (Johansen et al., 2011; John et al., 1999; Kondo et al.,
2000; Li et al., 2001; Shintani-Ishida et al., 2007). Cytokines, like
interleukin-1beta and tumor necrosis factor-alpha are released by
microglia under inflammatory conditions (Kettenmann et al.,
2011; Simi et al., 2007) inhibit Cx43 gap junctions, thereby
reducing intercellular communication between astrocytes while
enhancing Cx43-hemichannel activity, thereby increasing plasma
membrane permeability (Retamal et al., 2007a). The latter is based
on strong evidence using Cx43-knockout mice and Cx43-
hemichannel inhibitors. Interestingly, opposite functional out-
comes of cytokines on Cx43 gap junctions and hemichannels were
mediated by a common p38 mitogen activated protein kinase
pathway. The effects of cytokines on Cx43 hemichannels were
dependent on sulfhydryl oxidation reactions on Cx43, since
reducing agents like dithiothreitol counteracted these effects.
Moreover, these cytokines also resulted in increased Cx43-
hemichannel activity, despite the reduction in the total and
surface-available Cx43 levels upon cytokine treatment. The latter
finding is supported by electrophysiological experiments showing
that the unitary events of w220 pS corresponding to Cx43
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hemichannels were much more frequent in cytokine-treated as-
trocytes. Other studies found similar oppositely directed effects on
gap junctions and hemichannels. For instance, an augmented level
of intracellular oxidative stress (e.g. during ischemia/reperfusion)
decreased Cx43-mediated gap junction communication, but at the
same time increased Cx43-hemichannel activity by increasing the
open probability and the number of surface Cx43 hemichannels
(Retamal et al., 2006, 2007b, c). Again, this mechanism seemed to
depend on changes in the intracellular redox state, which may
modulate Cx43 hemichannels by influencing the three intracel-
lular Cys residues present on the C-terminal tail. In C6 glioma cells
ectopically expressing Cx43, some kinase-activating stimuli, like
the immunostimulating lipopolysaccharide (LPS) and basic fibro-
blast growth factor (bFGF), have been described to cause the in-
hibition of Cx43 gap junction channels, while stimulating the
release of ATP via Cx43 hemichannels (De Vuyst et al., 2007). An
independent study from Saez and co-workers clearly underpinned
these findings, showing that fibroblast growth factor-1 (FGF-1),
which is released in spinal cord injury, caused permeabilization
and ATP release of spinal cord astrocytes (Garre et al., 2010). This
ATP release was at least in part through the opening of Cx43
hemichannels (besides vesicular ATP release and Panx-mediated
ATP release). In contrast, interastrocyte coupling through Cx43
gap junctions was inhibited. These mechanisms may further pro-
mote inflammation and to contribute to the loss of protective ef-
fects of astrocytes on neurons. In any case, there seems ample
evidence that Cx43-based gap junction channels and hemi-
channels are oppositely regulated, as recently highlighted by the
differential action of growth factors on gap junctions and hemi-
channels (Schalper et al., 2012).
3.2. Loop and C-terminal tail modifications differentially affect
Cx43 gap junctions and hemichannels
Besides the evidence at the physiological level that Cx43-based
gap junction channels and hemichannels display opposite re-
sponses upon cellular signaling events, there are also a number of
molecular studies exploiting the expression of truncated, C-
terminally tagged or mutated Cx43 proteins (Fig. 4). These studies
point towards critical differences in the dependence of gap
junction channels versus hemichannels to intramolecular loop/tail
interactions for their activity. i) C-terminally truncated Cx43 is
able to form functional gap junction channels (De Vuyst et al.,
2007; Maass et al., 2007), which are even resistant to closure
upon intracellular acidosis (Morley et al., 1996). In contrast, C-
terminally truncated Cx43 hemichannels fail to form functional
hemichannels. The latter is supported by different types of evi-
dence. In electrophysiological experiments using cell-attached
patches and inside-out patches on C6 glioma cells ectopically
expressing Cx43, the opening of Cx43 hemichannels could be
detected and analyzed (Kang et al., 2008). However, truncating
Cx43 at Met257 resulted in loss of Cx43 hemichannel activity and
single-channel openings were not observed. This is further sup-
ported by other studies, showing that cells ectopically expressing
Cx43M239 or Cx43M257 display strongly reduced ATP release trig-
gered by decreasing extracellular [Ca2þ] using the Ca2þ buffer
EGTA (De Vuyst et al., 2007) or by increasing intracellular [Ca2þ]
using the Ca2þ ionophore A23187 (De Vuyst et al., 2009; Ponsaerts
et al., 2010) (Fig. 4). ii) GFP-tagging of Cx43 at its C-terminal tail
resulted in an increase of the gap junction-plaque size, and a
potentiation of gap junction communication (Bukauskas et al.,
2000; Hunter et al., 2003; Verselis and Bukauskas, 2002). Cx43-
GFP-based hemichannels displayed altered gating. For instance,
they only displayed slow gating between the fully closed and the
fully open state while the fast gating from the residual state to the
fully open state disappeared (Contreras et al., 2003; Kang et al.,
2008). These data correlate with the compromised ATP-flux
properties of Cx43-GFP-based hemichannels (Kang et al., 2008).
Yet, brief openings of the Cx43 hemichannels might occur as
ethidium bromide uptake was observed in Cx43-GFP-expressing
cells (Contreras et al., 2003). The latter has been confirmed in
studies showing that lowering the intracellular redox potential or
exposing cells to FGF-1 promotes the opening of Cx43 and Cx43-
EGFP-based hemichannels (Retamal et al., 2007b; Schalper et al.,
2008). In any case, the influence of GFP tagged to the C-terminal
tail of Cx43 on endogenous loop/tail interactions in Cx43 hemi-
channels ought to be further established. iii) Pathological muta-
tions in the L2 region of Cx43 have been identified in patients
suffering from oculodentodigital dysplasia. For instance, Cx43G138R
and Cx43G143S were found to be deficient in gap junction coupling,
while ATP-releasing hemichannel activity was promoted
(Dobrowolski et al., 2007). Hence, these mutations, which occur in
the L2 region, differentially affect Cx43 gap junctions and hemi-
channels. Thus, these data indicate that while Cx43 gap junctions
are closed by intramolecular loop/tail interactions, e.g. during
intracellular acidosis (Ek-Vitorin et al., 1996), Cx43 hemichannels
actually depend on intramolecular loop/tail interactions for their
opening in response to cellular stimuli (Ponsaerts et al., 2010). Yet,
at this stage, it is not clear whether these intramolecular loop/tail
interactions in Cx43 hemichannels are pre-established (even in
the absence of cellular stimuli) or whether stimuli that increase
Cx43-hemichannel opening (like depolarization, low extracellular
[Ca2þ] or moderate rises in intracellular [Ca2þ]) do it by triggering
the binding of the C-terminal tail to the intracellular loop. It is thus
conceivable that these cellular stimuli trigger conformational
changes in the Cx43-building blocks that facilitate the binding and
subsequent opening of the Cx43 hemichannels or that only the
conformation of Cx43 hemichannels in which loop/tail in-
teractions are established allows to sense the stimuli, resulting in
the opening of Cx43 hemichannels. The latter option definitely is
possible, since we found that the L2 region was able to bind the C-
terminal tail of Cx43 at physiological pH (Ponsaerts et al., 2010). In
any case, we postulate that the binding of the C-terminal tail to the
intracellular loop is not sufficient for the opening of Cx43 hemi-
channels, but requires an additional activating stimulus.
Fig. 4. TAT-CT10 is sufficient to restore the activity of C-terminally truncated Cx43
hemichannels. C-terminally truncated Cx43 hemichannels cannot be opened in
response to stimuli like an increase in intracellular [Ca2þ]. Yet, the addition of the last
10 amino acids is sufficient to open C-terminally truncated Cx43 hemichannels in
response to an increase in intracellular [Ca2þ]. It is important to note that the peptide
by itself is not sufficient to open the C-terminally truncated Cx43 hemichannels in the
absence of stimuli. For clarity reasons, the monomeric building blocks are depicted, but
it should be noted that the functional channel unit is hexameric.
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3.3. Intracellular loop peptides inhibit Cx43 hemichannels but not
gap junction channels
As discussed above, the L2 region in Cx43 acts as a receptor for
the C-terminal tail, which functions as a gating particle, underly-
ing the closure of gap junction channels during acidosis (Duffy
et al., 2002; Seki et al., 2004b). Synthetic L2 peptides promote
the opening of Cx43 gap junction channels (Duffy et al., 2002; Seki
et al., 2004b; Shibayama et al., 2006). Making use of the cell-
permeable TAT-coupled L2 peptide, we found that the L2 pep-
tide inhibited the opening of Cx43 hemichannels in response to an
extracellular [Ca2þ] decrease or an intracellular [Ca2þ] increase
without affecting gap junction coupling (Evans et al., 2012;
Ponsaerts et al., 2010) (Figs. 1 and 3). TAT-L2 inhibited Cx43-
hemichannel-mediated ATP release in response to a [Ca2þ] in-
crease brought about by 2 mM Ca2þ ionophore with an IC50 of
about 10 mM. Further studies led to the identification of a non-
apeptide variant of L2 peptide that displayed a certain degree of
endogenous cell-penetrating potential (Gap19) (Evans et al., 2012;
Wang et al., 2013b) (Fig. 3). The Gap19 peptide covers the region
between amino acids 128 and 136. Gap19 provoked Cx43-
hemichannel inhibition with an IC50 of about 50 mM, while not
blocking Cx43 gap junction channels (Wang et al., 2013b).
Coupling Gap19 to TAT facilitated its cell-penetrating properties
and provoked inhibition of Cx43-hemichannel responses with an
IC50 of less than 10 mM. Furthermore, Gap19 was selective for
Cx43-based hemichannels, since it had no effect on Cx40- and
Panx1-based hemichannels. These findings were supported by
electrophysiological experiments, demonstrating that Gap19
inhibit Cx43 hemichannel unitary currents in both HeLa cells
exogenously expressing Cx43 and acutely isolated pig ventricular
cardiomyocytes. Thus, Gap19 inhibition of Cx43 hemichannel
opening, activated by voltage, is likely the result of a shift of the
activation potential of hemichannel opening to more positive
potentials. Consistent with previous reports, we found that bio-
tinylated versions of L2 and Gap19 were able to bind the C-ter-
minal tail of Cx43, expressed and purified as a recombinant
protein, in surface plasmon resonance experiments (Wang et al.,
2013b). Thus, it seems that the binding of the C-terminal tail of
Cx43 hemichannels to its endogenous L2 receptor region in Cx43
is an absolute requirement for the opening of Cx43 hemichannels.
Preventing this binding using TAT-L2 or Gap19 resulted in the
inhibition of Cx43-hemichannel opening. Furthermore, a stretch of
nine amino acids within the L2 region seem to serve as a hot spot
for the interaction of the C-terminal tail, carrying critical elements
for intramolecular loop/tail-complex formation. Interestingly, the
amino acids present in Gap19 are largely positively charged
(KQIEIKKFK), thereby contributing to its intrinsic cell-penetrating
properties. Critical amino acids in Gap19 were I130 and K134,
since mutating these residues into Ala disrupted its ability to
inhibit Cx43 hemichannels. The influence of K134A mutation on
Gap19 function was tested in a mammalian expressing plasmid
encoding Flag-Gap19. The critical role of K134 fits well with the
presumed binding site at the C-terminal tail, namely the last nine
amino acids, in which negatively charged Asp residues have been
implicated in establishing loop/tail binding via ionic interactions
(Hirst-Jensen et al., 2007). Additionally, the critical role of I130 in
Gap19 in the inhibition of Cx43 hemichannels fits well with pre-
sumed structural integrity that is needed at this site to form alpha-
helical structures (Duffy et al., 2002). In addition, I130 may
contribute to the binding of the C-terminal tail via non-ionic in-
teractions. Consistent with these findings, Gap19I130A was much
less efficient in inhibiting Cx43 hemichannel unitary currents in
Cx43-expressing HeLa cells and adult pig cardiomyocytes con-
taining endogenous high levels of Cx43 (Wang et al., 2013b).
Finally, since cell-penetrating Cx43-loop peptides selectively
inhibit Cx43 hemichannels without blocking Cx43 gap junction
channels, they are ideal tools to target Cx43 hemichannels in
complex cellular systems or to demonstrate the contribution of
Cx43 hemichannels in cellular signaling processes (Evans et al.,
2012). In particular, traditional knockout or knockdown ap-
proaches prevent the expression of the Cx43 building blocks,
thereby affecting both Cx43 gap junction and hemichannels. As a
control for TAT-L2, it is recommended to use TAT-L2H126K/I130N, a
mutated version of TAT-L2 that is not able to bind the C-terminal
tail of Cx43 and thus does not interfere with loop/tail interactions.
3.4. C-terminal tail peptides restore the activity of Cx43M239
hemichannels
As discussed above, Cx43M239 hemichannels fail to open in
response to conditions that stimulate Cx43-hemichannel opening.
Strikingly, we found that a short peptide sequence covering the last
10 amino acids of the C-terminal tail (TAT-CT10) was sufficient to
restore the activity of Cx43 hemichannels that lack their complete
C-terminal tail (Ponsaerts et al., 2010). This was supported by ATP
release assays in Cx43M239-expressing C6 glioma and HeLa cells.
Further evidence was provided by electrophysiological measure-
ments in Xenopus oocytes, in which endogenous Cx38 was knocked
down and ectopic Cx43 was expressed (Ponsaerts et al., 2010).
Consistent with the original report showing that in Xenopus oocytes
expression of Cx43, in contrast to Cx46, does not induce depolari-
zation, lysis, permeability to Lucifer yellow and voltage-gated cur-
rents in non-junctional membranes (Paul et al., 1991), we
confirmed that Cx43 is not able to form functional hemichannels in
Xenopus oocytes (Ponsaerts et al., 2010). We have proposed that the
strong cortical actin cytoskeleton prevents the binding of the C-
terminal tail to the cytoplasmic loop domain, thereby hampering
the opening of Cx43 hemichannels (Ponsaerts et al., 2012b). Strik-
ingly, TAT-CT10 was able to overcome this inherent lack of loop/tail
interactions, thereby restoring the activity of Cx43 hemichannels as
determined in electrophysiology experiments in Xenopus oocytes
exogenously expressing Cx43 (Ponsaerts et al., 2010). The negative
regulation of Cx43-hemichannel activity by the actin cytoskeleton
via disrupting essential loop/tail interactions has been further
underpinned by a variety of experimental approaches. Thrombin
treatment of corneal endothelial cells inhibits Cx43-hemichannel-
driven intercellular Ca2þ-wave propagation via the cytoskeleton,
since (")-blebbistatin could alleviate this inhibitory effect
(Ponsaerts et al., 2008). Pre-incubating corneal endothelial cells
with TAT-CT10 completely alleviated thrombin-induced inhibition
of Cx43 hemichannels (Ponsaerts et al., 2010). Similarly, C6 or HeLa
cells ectopically expressing Cx43 display a bell-shaped dependence
towards intracellular [Ca2þ], with [Ca2þ] below 500 nM triggering
Cx43-hemichannel opening and with [Ca2þ] above 500 nM inhib-
iting Cx43-hemichannel opening (De Vuyst et al., 2009). The inhi-
bition of Cx43 hemichannels by high intracellular [Ca2þ] could be
completely alleviated by (")-blebbistatin (Ponsaerts et al., 2010). In
contrast, pre-incubating the cells with TAT-CT10 completely pre-
vented the inhibition of Cx43 hemichannels by high intracellular
[Ca2þ] (Ponsaerts et al., 2010). Correlating with this, TAT-CT10
restored the activity of Cx43M239 hemichannels, while (")-bleb-
bistatin did not. Thus, it seems that the last 10 amino acids of the C-
terminal tail harbor residues that are critical for loop/tail in-
teractions in Cx43 hemichannels. Hence, these findings reinforce
the necessity for the C-terminal tail of Cx43 for Cx43-hemichannel
activity (Ponsaerts et al., 2010). Moreover, these effects of TAT-CT10
were independent of its ability to bind the PDZ-2 domain of ZO-1.
Indeed, TAT-CT10DI, lacking the last isoleucine residue essential
for the binding of the PDZ-2 domain of ZO-1 (Giepmans and
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Moolenaar, 1998), was equally potent in i) restoring the activity of
Cx43M239-based hemichannels and ii) alleviating the inhibition of
Cx43-based hemichannels by high intracellular [Ca2þ] (Ponsaerts
et al., 2010). At the biochemical level, we demonstrated that a
biotinylated version of CT10 and CT10DI was able to interact with
the L2 region of Cx43 but not with the L2H126K/I130N variant
(Ponsaerts et al., 2010). Finally, while CT10 binding to L2 is required
for the opening of Cx43 hemichannels, it is not sufficient by itself to
induce Cx43-hemichannel opening (Ponsaerts et al., 2010). Indeed,
TAT-CT10, by itself, did not open Cx43M239 hemichannels in the
absence of stimuli like low extracellular [Ca2þ] or increased intra-
cellular [Ca2þ].
Very recently, we identified the residues in TAT-CT10 critical for
its activity to regulate Cx43 hemichannels (D’hondt et al., 2013).We
found that mutating Asp378 and Asp379 into Ala residues abol-
ished TAT-CT10’s ability to alleviate the inhibition of Cx43 hemi-
channels by high intracellular [Ca2þ] and to restore Cx43M239-
hemichannel activity in response to moderate rises in intracellular
[Ca2þ]. Similar results were obtained by mutating Pro375 and
Pro377 into Gly residues. On the other hand, mutating Arg374 and
Arg376 into Ala residues did not alter the functional properties of
TAT-CT10 on Cx43 hemichannels. Thus, it seems that at least
negatively charged Asp residues and their proper structural orga-
nization via Pro residues are critical determinants to establish loop/
tail interactions involving the CT10 region.
3.5. Cell-permeable loop peptides and C-terminal tail peptides
neutralize each other’s action
Finally, the inhibition of Cx43 hemichannels by TAT-L2 or Gap19
can be completely neutralized by co-incubating the cells with TAT-
CT10 (Ponsaerts et al., 2010; Wang et al., 2013b). Consistent with
the importance of ionic and non-ionic interactions, the neutrali-
zation of Gap19’s inhibitory properties on Cx43 hemichannels by
TAT-CT10 was dependent on the presence of two Pro residues
(amino acids 375 and 377) and two Asp residues (amino acids 378
and 379) (Wang et al., 2013b). The importance of these residues in
the CT10 sequence for binding the cytoplasmic loop domain ought
to be further examined in in vitro binding experiments, like surface
plasmon resonance. Vice versa, the ability of TAT-CT10 to overcome
the inhibition of Cx43 hemichannels in response to high intracel-
lular [Ca2þ] is ablated by co-incubating the cells with TAT-L2
(Ponsaerts et al., 2010). These findings are mechanistically sup-
ported by the ability of biotin-CT10 immobilized to a streptavidin-
coated sensor chip to bind TAT-L2 in in vitro binding experiments
based on surface plasmon resonance.
3.6. Applications of cell-permeable loop and C-terminal tail
peptides to tackle Cx43 hemichannel functions in complex cellular
systems and pathophysiological conditions
3.6.1. L2
There has been increasing evidence from in vitro and ex vivo
studies that astrocytes are involved in synaptic plasticity and may
contribute to synaptic activity via the release of neuroactive glio-
transmitter substances, including D-serine, glutamate, and ATP
(Fellin et al., 2006; Scolari and Acosta, 2007; Verkhratsky and
Parpura, 2010; Volterra and Meldolesi, 2005). In addition, gluta-
mate released from astroglial cells has been shown to affect
neurotransmitter release at the synaptic cleft (Santello et al., 2012).
Unfortunately, due to the lack of selective Cx43-hemichannel in-
hibitors and the fact that Cx43-knockout animals lack both gap
junction channels and hemichannels, the role of Cx43 hemi-
channels in the release of gliotransmitters from astrocytes and their
relevance for the control of higher brain function in vivo is still an
open question (Stehberg et al., 2012). Recently, we exploited the
biophysical properties of TAT-L2 to assess whether Cx43 hemi-
channels are involved in the release of gliotransmitters under
in vivo conditions. This approach was possible because this peptide
did not affect the neuronal components of synaptic transmission,
which do not express Cx43, nor did the peptide influence gap
junction coupling between neighboring astrocytes. The TAT-L2
peptide was micro-injected in the basolateral amygdala, a region
of the brain involved in the processing of emotion, more specifically
fear and fear memory (Stehberg et al., 2012). Using an auditory fear
conditioning training protocol (a conditioned sound stimulus
shortly followed by an unconditioned electrical shock stimulus),
proper memory consolidation was assessed 24 h after the training
by providing the conditioned sound stimulus only (Stehberg et al.,
2012). Strikingly, TAT-L2, but not TAT-L2H126K/I130N, completely and
potently blocked fear memory consolidation and provoked a
complete amnesia towards the auditory fear conditioning. Con-
centrations as low as 10 nM TAT-L2 proved to be effective in trig-
gering amnesia. These effects of TAT-L2 were transitory and did not
affect the short-term memory aspects of the fear conditioning
paradigm. Also, the amnesic effects of TAT-L2 were only provoked
when administered during the period of memory consolidation
(within the first 4 h after the auditory fear conditioning training
protocol). Moreover, inhibition of fear memory by TAT-L2 dis-
appeared by supplementing TAT-L2 with an exogenous cocktail of
putative gliotransmitters (including glutamate, glutamine, lactate,
D-serine, glycine, and ATP). These data demonstrate the potential of
TAT-L2 as a tool to help unraveling the contribution of Cx43 hem-
ichannels in complex biological systems like the brain.
3.6.2. Gap19
Gap19 is a nonapeptide variant of TAT-L2 that displays intrinsic
cell-penetrating activities and selectively inhibits Cx43 hemi-
channels (Fig. 2) (Evans et al., 2012; Wang et al., 2013b). Impor-
tantly, Gap19 (100 mM) strongly inhibited unitary Cx43-
hemichannel currents in freshly isolated cardiomyocytes (Wang
et al., 2013b). Moreover, Gap19 also inhibited the promotion of
unitary hemichannels currents when the cardiomyocytes were
subject to metabolic inhibition by applying a combination of
mitochondrial uncoupler and a glycolysis inhibitor (chemical in-
hibition) (Wang et al., 2013b). This was further tested both in vitro
and in vivo in ischemia, which is known to promote deleterious
Cx43-hemichannel activity in a redox and phosphorylation-
dependent manner (Wang et al., 2013b). In those experiments, it
was hypothesized that excessive opening of Cx43 hemichannels
results in cell death due to the loss of energy, ionic and metabolic
gradients (Evans et al., 2006). In freshly isolated cardiomyocytes,
addition of Gap19 before exposure to oxygen-glucose deprivation/
acidosis followed by reperfusion, improved the cell viability
and prevented cell swelling (Wang et al., 2013b). Importantly,
Gap19I130A was much less potent than Gap19 in suppressing cell
death and swelling. Finally, in in vivo myocardial ischemia/reper-
fusion applied to mice by ligation of the left anterior descending
coronary artery followed by reperfusion, Gap19, but not Gap19I130A
(250 mM, added 10 min before ligation), significantly reduced the
infarct size. These are promising observations, indicating that the
opening of Cx43 hemichannels in the plasma membrane may
indeed contribute to ischemia/reperfusion damage in the heart. It is
essential here to underscore the fact that gap junction channels are
not inhibited by Gap19; in the heart but also in the brain, inhibition
of gap junctions would result in significant confounding effects,
making interpretation of the experimental results problematic.
Hence, Gap19 inhibition of Cx43 hemichannels, combined with
work on the Cx43G138R mutant that is linked to promoted hemi-
channel activity (Dobrowolski et al., 2007) offers an interesting set
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of tools to explore the role of Cx43 hemichannels in various phys-
iological and pathological conditions. Moreover, Gap19 and L2
peptides not only have specificity toward hemichannels, but also
toward the specific type of Cx. Indeed, the sequences mimicked by
these peptides are located on the cytoplasmic loop of the Cx pro-
tein; these sequences are very different between different Cx types.
In line with this, we found that Gap19 blocked Cx43 hemichannels
but not those composed of Cx40 or Panx1 (Wang et al., 2013b).
3.6.3. CT peptides
TAT-CT10 is a cell-permeable peptide that corresponds to the
last 10 amino acids of the C-terminal tail of Cx43 and prevents the
inhibition of Cx43 hemichannels by high intracellular [Ca2þ]
(Ponsaerts et al., 2010). This correlates with previous findings
showing that the high intracellular [Ca2þ]-mediated inhibition of
Cx43 hemichannels can be alleviated by using i) TAT-CT10DI, which
lacks the last isoleucine (Ponsaerts et al., 2010) or ii) the CT9 pep-
tide, which corresponds to the last 9 amino acids of the C-terminal
tail and does not contain Ser373 (De Bock et al., 2012). CT9 is not
cell-permeable and ought to be loaded in intact cells via other
means, like electroporation approaches (De Vuyst et al., 2008) or
cationic lipid-mediated transfer. Furthermore, it is important to
note that ACT1, developed by Gourdie and co-workers, corresponds
to the CT9 sequence, but linked to a different cell-penetrating motif
that is based on the antennapedia sequence (Hunter et al., 2005;
O’Quinn et al., 2011). Thus, TAT-CT10, CT9 and ACT1 converge by
sharing the last 9 amino acids of the C-terminal tail of Cx43,
harboring the critical elements for binding the L2 region in Cx43
hemichannels. Table 1 provides an overview of the sequences of
these peptides.
Recently, CT9 has been used to assess the contribution of Cx43
hemichannels to sustain agonist-induced Ca2þ oscillations (De Bock
et al., 2012). It was found that Ca2þ oscillations triggered by bra-
dykinin, but not those triggered by extracellular ATP, were depen-
dent on Cx hemichannels. These two agonists, and the associated
two different Ca2þ oscillation mechanisms and patterns, appeared
to also have a differential effect on the permeability of bloodebrain
barrier endothelial cells, with bradykinin increasing the perme-
ability and ATP having no effect (De Bock et al., 2011). Using CT9
peptide and other peptides mimicking extracellular loop domains
(Gap26 and/or Gap27), it was found that i) Ca2þ entry via Cx43
hemichannels is essential in bradykinin-triggered Ca2þ oscillations,
and ii) the bell-shaped dependence of Cx43 hemichannels to
intracellular [Ca2þ] is critical sustain Ca2þ oscillations. Thus, Ca2þ
signals from the ER will rise cytosolic [Ca2þ] above 100 nM, thereby
opening Cx43 hemichannels and providing a Ca2þ influx pathway
(De Vuyst et al., 2009). As a result, cytosolic [Ca2þ] will further rise
till 500 nM and higher, which will lead to the closure of Cx43
hemichannels and closure of the Ca2þ entry pathway. It is inter-
esting to note that IP3Rs too display a bell-shaped dependence to
intracellular [Ca2þ] in the similar range as for Cx43 hemichannels,
with low cytosolic [Ca2þ] being stimulatory and high cytosolic
[Ca2þ] being inhibitory (Bezprozvanny et al., 1991; Iino, 1990).
Finally, consistent with our previous findings showing that in-
teractions between the CT peptides and the L2 region were inde-
pendent of the last isoleucine and that inhibition of Cx43
hemichannels too could be alleviated by TAT-CT10DI (Ponsaerts
et al., 2010), CT9DI too disrupted bradykinin-induced Ca2þ oscilla-
tions (De Bock et al., 2012). Thus, the effects of the CT peptides on
Ca2þ oscillations are not due to the disruption of Cx43/ZO-1 in-
teractions. In fact, ZO-1 maymainly bind to Cx43 gap junctions and
not hemichannels, as we failed to detect ZO-1 co-immunoprecipi-
tation with Cx43 hemichannels (Ponsaerts et al., 2010).
3.6.4. Therapeutic applications for selective Cx43-hemichannel
inhibitors
Definitely, given the emerging role of Cx43 in the spreading of
cell death (Decrock et al., 2009a,b, 2011, 2012), TAT-L2 and derived
peptides (like Gap19) and other small inhibitory molecules have
therapeutic potential in ischemia/reperfusion injury in the brain or
heart. They may reduce tissue damage from excessive cell death
and its spread, by limiting excessive Cx43-hemichannel opening,
while maintaining gap junction coupling. Importantly, Gap19
reduced the detrimental outcome of ischemia/reperfusion in iso-
lated cardiomyocytes in vitro and in the heart in vivo. This further
highlights the therapeutic potential of inhibiting Cx43 hemi-
channels and underpins the favorable outcomes obtained with
other Cx-mimetic and -inhibiting peptides, Gap26 and Gap27. For
instance, Gap26 administered before or after the occurrence of
ischemia or as single intravenous low-dose injections protected the
intact heart against ischemia-reperfusion injury (Hawat et al., 2010,
2012). Likely, therapeutic applications of L2/Gap19 peptide or like
molecules are not limited to the heart, but could also be neuro-
protective. For instance, Peptide5 which is mimetic peptide that
overlaps with the Gap27 domain, displayed protective effects
against detrimental events following retinal ischemia/reperfusion,
including a reduction in endothelial cell death, reduced vascular
leakage and increased retinal ganglion cell survival in the injured
retina (Danesh-Meyer et al., 2012). Inhibition of Cx43 hemichannels
is also favorable to reduce inflammation by suppressing the release
of inflammatory cytokines and to prevent secondary tissue damage
by suppressing neuronal death after cerebral or spinal cord injuries
(Huang et al., 2012; O’Carroll et al., 2008, 2013). Mechanistically,
inflammatory cytokines released from microglia, like IL-1b and
TNF-a, increase astrocytic Cx43-hemichannel activity (Retamal
et al., 2007a). The latter will be responsible for post-traumatic
ATP release, which will result in neuronal death through the acti-
vation of Panx1 (Orellana et al., 2011a) and which has been impli-
cated in aggravated secondary injury and restrained functional
recovery (Huang et al., 2012). Thus, inhibition of excessive astro-
cytic Cx43-hemichannel activity in response to inflammatory
cytokine released from microglia upon injury has neuroprotective
potential (Froger et al., 2010). In particular, L2/Gap19-derived tools
might be preferentially used over Gap26/Gap27 Cx-mimetic pep-
tides, since L2/Gap19 may useful to counteract the concomitant
inhibition of metabolic coupling due to gap junction inhibition
observed during many of these conditions (Meme et al., 2006;
Retamal et al., 2007a).
L2/Gap19 or derived molecules might also be useful in other
types of injury. For instance, the cryopreservation/thawing process
of arteries and veins affects the integrity of the intimal layer and the
cell viability of the endothelial cells. Application of Gap27 that
Table 1
An overview of the different C-terminal Cx43 peptides. All peptides contain a common sequence that corresponds to the last 9 amino acids of the C-terminal tail of Cx43. The
underlined sequence corresponds to the cell-penetrating motif that is fused to the Cx43 sequence (Antennapedia for ACT1 and TAT for TAT-CT10).
Peptide name Peptide sequence Developed by References
ACT1 RQPKLWFPNRRKPWKKRPRPDDLEI Gourdie and co-workers (Hunter et al., 2005;
O’Quinn et al., 2011)
TAT-CT10 YGRKKRRQRRRSRPRPDDLEI Bultynck, Leybaert and co-workers (Ponsaerts et al., 2010)
CT9 RPRPDDLEI Bultynck, Leybaert and co-workers (De Bock et al., 2012)
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targets both Cx43 and Cx37 channels during the cryopreservation/
thawing process significantly improves the conservation of the
intimal layers and reduces cell death in the endothelial cells as well
as smooth muscle cells. Hence, TAT-L2 (or Gap19) as a selective
Cx43 inhibitor could also be used. Yet, since other Cx isoforms are
expressed in the vasculature that are not targeted by TAT-L2 (or
Gap19), like Cx37, the use of TAT-L2 (or Gap19) as a single agent
would likely be insufficient.
Moreover, the application of these peptide tools may not be
limited to counteract damage or injury by ischemia/reperfusion,
but may also be relevant for neurodegenerative diseases, like Alz-
heimer’s disease. Amyloid b not only potentiates the action of in-
flammatory cytokines released from microglia on astrocytic Cx43
hemichannels (Meme et al., 2006), but may also increase the
presence of Cx43 on the cell surface (Mei et al., 2010). Amyloid b has
been proposed to trigger a “toxic” signaling cascade that is driven
by hemichannel activation in glial and neuronal cells. Thus, in-
flammatory cytokines from microglia may promote the release of
glutamate and ATP through glial (microglia and astrocytes) hemi-
channels, thereby triggering the deleterious opening of neuronal
hemichannels and resulting in neuronal cell death. Thus, L2/Gap19
or derived peptides may provide unprecedented avenues to pre-
vent the toxic Cx43-hemichannel activity in glial cells, thereby
promoting the survival of neuronal cells in the presence of Ab
(Orellana et al., 2011b).
Finally, beyondneurodegenerative diseases, L2/Gap19 or derived
molecules might be applicable to interfere with the essential role of
Cx43 hemichannels in the release of gliotransmitters during fear
memory consolidation (Stehberg et al., 2012). As such, tools that
selectively inhibit Cx43 hemichannels may provide a novel strategy
for the future treatment of psychiatric disorders, including anxiety
and post-traumatic stress disorders.
3.7. Concerns associated with the use of peptides targeting Cx43
hemichannels
While these peptide tools are particularly useful in biological
research, it is important to note that there are a number of limi-
tations associated to their use.
3.7.1. Stability
As for all peptides composed of natural amino acids, it is
important to realize that these peptides might be unstable and/or
degraded upon prolonged cellular incubations, thereby losing their
activity. Yet, it seems that these peptide sequences remain quite
stable at least for hours (Ponsaerts et al., 2010). For instance, pro-
longed incubation of Gap19 for 24e48 h in Cx43-expressing C6-
glioma cells promoted dye coupling using FRAP experiments,
while completely blocking ATP release in response to moderate
intracellular [Ca2þ] rises (Wang et al., 2013b). Regarding potential
clinical uses, the peptides are likely to be degraded rapidly, limiting
their usability to only short and localized therapeutic applications.
Additionally, the peptides are expected to nonspecifically bind
plasma components when administered via the I.V. route.
3.7.2. Selectivity
Another concern is the selectivity of these Cx43-hemichannel-
modulating peptides towards other Cx and/or Panx isoforms.While
a complete profile of the effect of these peptides on other Cx and
Panx isoforms has not been performed, it is important to consider
that the sequences corresponding to the L2 (and Gap19) region and
the CT10 region are hyper variable sequences with very low ho-
mology between the different Cx and Panx isoforms. This is also
evident from Table 2, which provides an overview of the results
obtained from a BLAST search using the human Cx43 sequence.
Even Cx isoforms closely related to Cx43 (like Cx37, Cx46, Cx40,
Cx50 and Cx62) display a very high heterogeneity in their “L2
sequence”, while some resemblance of the “CT10” sequence of Cx43
could only be found in Cx46 and Cx40. Thus, from this analysis, it is
very unlikely that TAT-L2 and Gap19, which target the CT10 region
in Cx43, will affect other Cx-based hemichannels, although this
ought to be scrutinized for Cx46- and Cx40-based hemichannels.
Yet, our recent experiments indicate a critical role for the two Pro
residues in the CT10 region of Cx43 to establish interactions with
the intracellular loop region and these Pro residues do not seem to
be present in the CT10 region of Cx46 and Cx40 (D’hondt et al.,
2013). Also the TAT-CT10 peptides likely display a high selectivity
towards Cx43 hemichannels, given the very low resemblance of the
L2/Gap19 region between Cx43 and other Cx isoforms. Not only
sequence analysis seems to hint toward Cx43-selective tools, but
also experimental analysis supports this claim. For instance, Gap19,
in contrast to the established Panx1-inhibitory peptide 10Panx1, did
not inhibit Panx1-mediated ATP release from C6-glioma cells
ectopically expressing Panx1 in response to high extracellular [Kþ]
(Wang et al., 2013b). Gap19 also did not affect Cx40-hemichannel-
mediated ATP release in response to elevated intracellular [Ca2þ]
(Wang et al., 2013b). On the other hand, we found that a peptide
corresponding to the sequence of the L2 region in Cx50 did not
affect Cx43-hemichannel-driven intercellular Ca2þ-wave propaga-
tion (Ponsaerts et al., 2010).
3.7.3. Incomplete inhibition
At the electrophysiological level, the unitary currents provoked
by Cx43 hemichannels in Hela-Cx43 cells or ventricular car-
diomyocytes were severely reduced by Gap19 incubation but were
not completely inhibited, even not at high concentrations (Wang
et al., 2013b). This is in contrast with the experiments that assess
Cx43-hemichannel function bymeasuring ATP release, intercellular
Ca2þ wave propagation and dye uptake, showing that Gap19 (and
L2 peptide) impose a complete inhibition of these responses
Table 2
BLAST results obtained by searching database UniProtKB/Swiss-
Prot(swissprot) using PSI-BLAST (Position-Specific Iterated BLAST) by
entering the human Cx43 sequence and limiting the output to human
sequences (Altschul et al., 1997). The table only shows the regions cor-
responding to the L2 (Gap19 sequence is underlined) and CT10 region of
human Cx43.
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(Ponsaerts et al., 2010; Wang et al., 2013b). Thus, the passage of
large signaling molecules (like ATP, which has a molecular weight
of 507 Da) may be more affected by these peptide tools than ions.
This is in line with previous observations, showing that PKC-
dependent phosphorylation of Cx43 hemichannels restricts the
passage of sucrose (molecular weight of 342 Da) but not that of
ethyleneglycol (molecular weight of 62) (Bao et al., 2007). Alter-
natively, the inhibition of ATP release by Gap19 and L2might reflect
a non-linear event, since a 50% reduction of the Cx43 levels is
sufficient to completely prevent ATP release (De Vuyst et al., 2009).
3.7.4. High concentrations
The TAT-L2, Gap19 and TAT-CT10/CT9 peptide tools require
relatively high concentrations to induce their effects on Cx43
hemichannels. In most of our experiments, 100 mM of TAT-L2 or
TAT-CT10/CT9 was needed to achieve complete effects (Ponsaerts
et al., 2010). TAT-L2 inhibited Cx43-hemichannel-mediated ATP
release with an IC50 of about 11 mM, while TAT-CT10 restored
Cx43M239-hemichannel-mediated ATP release with an EC50 of
about 10 mM (Ponsaerts et al., 2010). This likely reflects four aspects:
i) the efficiency of cell-entry of these tools; ii) the distribution of
these peptides inside the cells with likely a major part of these
peptides accumulating in sites/compartments devoid of Cx43
hemichannels; iii) the binding of these peptides to the distinct Cx43
regions; and iv) the low intrinsic affinity of intramolecular loop/tail
interactions. In in vitro experiments, EC50 values of about 3 mM
were obtained for the binding of the C-terminal tail of Cx43 to
biotin-L2 and biotin-Gap19 (Wang et al., 2013b). Thus, the relatively
high IC50 values (about 50 mM) obtained for native Gap19 to inhibit
Cx43-mediated ATP release likely reflect its sub-optimal cell-entry
properties (Wang et al., 2013b). Consistent with this, improving
Gap19’s cell-entry properties by coupling it to the TAT sequence
significantly lowered this IC50 value (Wang et al., 2013a,b; see
supplementary material). In any case, the use of proper control
peptides like inactive mutants (TAT-L2H126K/I130N, Gap19I130A, or
TAT-CT10D377A/D378A) or scrambled/reversed sequence peptides are
essential to assess non-specific effects. Further support for the in-
crease in cell-entry properties by the use of peptide coupling with
TAT sequence comes from in vivo experiments, where TAT-L2 mi-
cro-injected into the basolateral amygdala had significant amnesic
effects in memory consolidation when injecting as low as 10 nM of
TAT-L2 (Stehberg et al., 2012). Although it is technically challenging
to evaluate the effects of the peptide on Cx43 hemichannel opening
in vivo, the physiological effectiveness of TAT-L2 at 10 nM, while
TAT-L2H126K/I130N was without effect, ascertains the peptide’s direct
actions on Cx43 hemichannels and rules out pleiotropic effects.
Also, these data suggest that a decrease in Cx43 hemichannel ac-
tivity can have important physiological effects without necessarily
requiring the complete silencing of the hemichannels.
4. Perspectives and conclusions
Thus, it is clear that intramolecular interactions between the C-
terminal tail and the cytoplasmic loop of Cx43 critically control the
activity of gap junction channels and hemichannels but with a
different outcome. In gap junctions occurs the binding of the C-
terminal tail to the cytoplasmic loop during pathological conditions
like acidosis, leading to the closure of gap junction channels. In
contrast, in hemichannels, the binding of the C-terminal tail to the
cytoplasmic loop is essential for the opening of Cx43 hemichannels
in response to different cellular stimuli, including increases in
cytosolic [Ca2þ] in the physiological range (between 100 nM and
500 nM). Interestingly, the same molecular determinants underlie
loop/tail binding in gap junctions and hemichannels, including at
least the L2 region as the receptor and the CT10 region as part of the
particle. As a consequence, peptides targeting these regions seem
to provoke opposite effects. For instance, TAT-L2 promotes gap
junction channel opening and prevents its closure during acidosis
and inhibits hemichannel opening in response to cellular stimuli.
This opens novel scientific and therapeutic perspectives to use TAT-
L2 and peptide variants to selectively inhibit Cx43 hemichannels
while maintaining Cx43 gap junction channels. Therefore, TAT-L2
and its nonapeptide variant Gap19 can be used as a selective
Cx43-hemichannel inhibitor in cellular models and organs to
pinpoint the contribution of Cx43 hemichannels in cell biological
and physiological processes. In the brain and the heart, these
peptides can be applied to counteract excessive hemichannel ac-
tivity during ischemia/reperfusion or metabolic inhibition, while
sustaining gap junction communication, essential for action po-
tential spreading in the heart or glucose spreading within astrocyte
layers. Furthermore, the recently discovered role of Cx43 hemi-
channels in fear memory consolidation highlights the potential of
TAT-L2/Gap19 as attractive lead compounds to tackle various psy-
chiatric and neurological disorders where excessive hemichannel
function is part of the pathophysiological problem.
Nevertheless, a number of questions remain about intra-
molecular loop/tail interactions regulating Cx43 hemichannels. For
instance, it is not known whether in analogy to gap junction
channels other regions in the C-terminal tail besides the CT10
amino acid stretch are involved in binding to the L2 receptor region.
It is also not clear how binding of the C-terminal tail to the cyto-
plasmic loop leads to opening of Cx43 hemichannels but closure of
Cx43 gap junction channels. This likely involves differences in
conformation between undocked hemichannels and head-to-head-
docked gap junction channels, pointing to an important role for the
extracellular loops. Moreover, it is not clear whether the C-terminal
tail is always bound to the cytoplasmic loop or whether the binding
is induced upon exposure to stimuli like strong depolarization,
extracellular Ca2þ buffers or intracellular Ca2þ-mobilizing agents.
In any case, since Cx43 hemichannels can permeate Ca2þ and thus
influence intracellular [Ca2þ] and intracellular [Ca2þ] influence
Cx43-hemichannel opening, it will be critical to assess the role of
intracellular Ca2þ in loop/tail interactions. Ca2þ may directly affect
the conformation of the cytoplasmic loop or C-terminal tail,
thereby altering their binding properties, or may indirectly affect
loop/tail interactions through Ca2þ-binding proteins, like calmod-
ulin, which binds near the L2 region or through Ca2þ-dependent
phosphorylation/dephosphorylation processes. In addition, intra-
cellular Ca2þmay also alter the ability of C-terminal tail to dimerize,
an essential step in binding L2 in gap junctions. Yet, the importance
of C-terminal tail dimerization for the opening Cx43 hemichannels
or rendering them in an activatable state remains elusive. Finally,
until know, all of our evidence has been obtained with Cx43
hemichannels, but it is not clear whether hemichannels formed by
other Cx isoform too are controlled by loop/tail interactions. A
likely candidate that might be controlled by loop/tail interactions is
Cx32, since Cx32 hemichannels too display a bell-shaped depen-
dence towards intracellular [Ca2þ] (De Vuyst et al., 2006).
In conclusion, loop/tail interactions in Cx43 involving the L2 and
CT10 regions are an important switch that turns off Cx43 gap
junction channels, while turning on Cx43 hemichannels, leading to
opposite outcomes. These interactions can be exploited by Cx43-
mimetic peptides that target these hot spots for interactions,
thereby leading to unprecedented opportunities to inhibit Cx43
hemichannels while maintaining Cx43 gap junction coupling.
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